Paseman & Associates
Paseman & Associates is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Paseman & Associates.
Paseman & Associates is a company.
Key people at Paseman & Associates.
Key people at Paseman & Associates.
Paseman & Associates is an angel investment firm led by Bill Paseman, focusing on early-stage investments in startups, particularly in Silicon Valley.[4][5] The firm emphasizes supporting high-potential teams by leveraging Paseman's extensive experience since 1980, with an investment philosophy centered on minimizing risk through strong business plans and quantitative finance insights, such as extensions to Modern Portfolio Theory.[5][8] Key sectors include healthcare and biotech, as evidenced by recent investments like $41.9 million in Cresilon's Series A for hemostatic products in wound healing.[2] It plays a niche role in the startup ecosystem by providing angel capital to innovative biomedical and tech ventures, contributing to early traction for companies addressing unmet medical needs.[1][2]
Bill Paseman founded Paseman & Associates as a personal angel investment vehicle after arriving in Silicon Valley in 1980.[4][5] With a background in quantitative finance—dating back to 1978 correspondence on topics like Ed Thorpe's theories and portfolio models—Paseman transitioned into angel investing, sharing resources on his site for corporate goals, team expectations, and risk reduction in startups.[5][8] The firm's evolution reflects Paseman's long-term Silicon Valley presence, shifting from personal finance explorations to active early-stage investments, including high-profile healthcare deals like Cresilon in 2025.[2][4]
Paseman & Associates rides the wave of biotech innovation, particularly in underserved areas like wound healing and oncology, amid surging demand for advanced medical devices post-2020s health crises.[2] Timing aligns with 2025's venture boom in healthcare tech, where firms like Cresilon benefit from market forces such as aging populations and minimally invasive procedure trends.[2] By funding pivotal Series A rounds, it influences the ecosystem through de-risking startups, enabling follow-on investments from larger VCs and accelerating tech transfer from labs to clinics.[1][2][8]
Paseman & Associates is poised to deepen its healthcare portfolio amid AI-driven drug discovery and precision medicine trends, potentially expanding into adjacent tech like imaging (e.g., Leadoptik analogs).[2][5] Rising interest in quantitative tools for volatile markets could amplify its influence, with Paseman's models aiding resilient startup funding. As angel capital bridges seed-to-growth gaps, expect evolved impact through co-investments, sustaining its niche in Silicon Valley's enduring startup engine—echoing its risk-focused roots for enduring returns.[5][8]